BioTelemetry, Inc. Announces Sales Agent Agreement with Boston Scientific Corporation
July 30 2020 - 7:00AM
BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, today announced a
sales agent agreement with Boston Scientific (NYSE:BSX), a global
medical technology leader. With this agreement, BioTelemetry
becomes a sales agent in the United States for the Boston
Scientific LUX-Dx™ Insertable Cardiac Monitor (ICM) System to
an agreed upon subset of customers. The LUX-Dx ICM
System is the first ICM device with remote programming and
also offers a dual-stage arrythmia detection algorithm.
BioTelemetry will discuss further details about the relationship
during its second quarter earnings call scheduled for Thursday,
July 30 at 5:00 p.m. Eastern.
BioTelemetry is the market leader in the wearable cardiac
diagnostic monitoring space and provides its Independent Diagnostic
Testing Facility (IDTF) services to customers that do not have the
capacity or capability to monitor their device patients. This
sales agent agreement adds ICM to its already diverse device
portfolio of Holter, Extended Holter and Event monitors, and its
flagship Mobile Cardiac Outpatient Telemetry (MCOT™) monitor.
The United States ICM market is large and growing, and with this
solution, both companies can access an expanded customer base while
maintaining focus on their core businesses.
“We are delighted to work with Boston Scientific and a team that
is as committed as we are about improving the lives of the people
we serve,” said Joseph H. Capper, President and CEO of
BioTelemetry. “Together, we are delivering solutions that
leverage our collective expertise, and providing access to a full
portfolio of flexible cardiac care solutions to meet physician and
patient needs in an unprecedented way.”
BioTelemetry processes over four billion heartbeats per day and
monitors over one million patients each year. It is the
pioneer in remote patient monitoring, revolutionizing healthcare
with its suite of cardiac monitoring devices and cloud-based
vendor-neutral remote monitoring platform, including its
FDA-cleared ePatch™ and MCOT™ monitors. BioTelemetry advances
health by providing technology and services that enable healthcare
providers to monitor and diagnose patients and clinical research
subjects in a more efficient, accurate and cost-effective
manner.
About BioTelemetry BioTelemetry, Inc. is
the leading remote medical technology company focused on delivery
of health information to improve quality of life and reduce cost of
care. We provide remote cardiac monitoring, centralized core
laboratory services for clinical trials, remote blood glucose
monitoring and original equipment manufacturing that serves both
healthcare and clinical research customers. More information
can be found at www.gobio.com.
Heather C. GetzInvestor RelationsExecutive Vice
President, Chief Financial
Officer800-908-7103investorrelations@biotelinc.com
Amy M. KnappMedia RelationsVice President,
Corporate Communications813-277-8456amy.knapp@gobio.com
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Sep 2023 to Sep 2024